The PRISM 2 consortium consists of world leading preclinical and clinical experts that form a highly collaborative team with an existing track record of fruitful EU-funded research projects. This includes the successful implementation and completion of the PRISM 1 project, which the PRISM 2 project is based on.
With 12 partners in Europe and 2 partners in the United States of America (USA), the PRISM 2 consortium builds a strong multidisciplinary team of researchers from academic research institutions, pharmaceutical companies, and small and medium-sized enterprises (SMEs). The broad spectrum of expertise in the fields of neuroscience, psychiatry, neurology, and (epi-)genetics accelerates the knowledge transfer between academia, industry, and the general public. The team is spearheaded by the project coordinator Prof. Dr. Martien Kas (RUG) and the project leader Dr. Hugh Marston (BI).
The overarching goal of PRISM 2 is to advance research and create real-life benefit for patients suffering from neuropsychiatric disorders, especially Alzheimer Disease (AD), Schizophrenia (SZ), and Major Depressive Disorder (MDD).